A Prospective, Randomized, Single Blind, Parallel, Active Controlled, Multicentre, Non-Inferiority Phase III Study to Evaluate The Immunogenicity And Safety Of Live Attenuated Varicella Vaccine Of Sinovac Biotech Ltd, China Compared To VARIPED® Vaccine (Varicella Vaccine Live I.P By MSDPharmaceuticals Pvt Ltd, India) In Healthy Paediatric Subjects In India - NA

开始日期2024-06-18

申办/合作机构

Techinvention Lifecare Pvt Ltd.

CTRI/2024/06/068559 / Not yet recruiting临床3期

A Multicenter, Randomized, Observer-blind, Non-inferiority, Phase III Study to Evaluate the Immunogenicity and Safety of BoostagenREDTM (combined tetanus toxoid, reduced diphtheria toxoid, reduced recombinant pertussis vaccine) by BioNet-Asia compared to ADACEL® vaccine by Sanofi Pasteur Limited in Healthy Subjects Aged 4-65 years - NIL

开始日期2024-06-15

申办/合作机构

Techinvention Lifecare Pvt Ltd.

CTRI/2021/08/035344 / Completed临床3期

A Phase III, open label, multicenter, parallel group, randomized Clinical Study to compare the Immunogenicity and Safety of Euvichol-Plus vaccine with Oral Cholera Vaccine Shanchol in healthy adults and children above age of one year

开始日期2021-08-09

申办/合作机构

Techinvention Lifecare Pvt Ltd.

100 项与 Techinvention Lifecare Pvt Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Techinvention Lifecare Pvt Ltd. 相关的专利（医药）

登录后查看更多信息

项与 Techinvention Lifecare Pvt Ltd. 相关的文献（医药）

2023-01-19·JAC-Antimicrobial Resistance

P10 Phage-encoded lysins as promising antibacterials against uropathogenic Escherichia coli

作者: Shah, Sanket ; Das, Ritam ; Ahmed, Syed ; Chavan, Bhakti ; Bajpai, Urmi ; Hanif, Sarmad

AbstractBackgroundUrinary tract infections (UTIs) represent a major public health issue. Uropathogenic Escherichia coli (UPEC) is a pathogen implicated in the vast majority of UTIs. Although treatable, the rampant and indiscriminate use of antibiotics has led to an alarming emergence of MDR strains. This can lead to complications, treatment failure, and increased rates of mortality and morbidity. Given the prevalence of these strains, we are exploring phage encoded-lysins as potential alternatives to antibiotics.ObjectivesOur study involved the development of an in silico strategy for the discovery and characterization of prophage-derived lysin sequences targeting the E. coli cell wall and evaluating the antibacterial activity of the recombinant lysins using in vitro assays.MethodsNovel lysin sequences were searched by BLAST homology and by screening E. coli prophages in the database (using PHASTER). They were computationally characterized and their domain architecture was examined. Based on the desired physicochemical properties of the 16 lysins, 7 were selected for cloning, expression, and purification as recombinant proteins for the in vitro antibacterial activity.ResultsIn silico analysis showed lysozyme-like domain in 9 out of 16 lysins and the predicted structure was either modular or globular. Cationic and hydrophobic residues at the C-terminal end and cationic residues in the catalytic domains indicate intrinsic bactericidal activity. Lysins (7) were cloned in pET28 vector and purified as His-tagged recombinant proteins by Ni-NTA chromatography. Using spot assay, 3 out of 7 lysins (9–12 μg) showed lysis of E. coli cells (BL21 DE3). The most promising was lysin sequence 5, which showed lysis of E. coli cells, both at stationary as well as mid-log phase cells. Turbidity reduction assay showed a 74.94% drop in OD600 in lysin (15 μM) treated cells after 3 h of incubation, at 37°C. Log killing assay showed 4 log10 reduction in the treated cells. Lysozyme assay demonstrates higher than / comparable lysozyme activity of lysin sequence 5 with the positive control.ConclusionsSixteen novel prophage-encoded lysin sequences have been identified to create a lysin bank (to screen against E. coli), and 7 of them have been purified. Screening shows three lysins having intrinsic bactericidal activity and hence did not require the addition of an Outer Membrane Permeabilizer (OMP). Lysin sequence 5 has exhibited the highest activity against E. coli cells. Enzyme stability and kinetics studies and screening of clinical isolates of E. coli from UTI patients is underway. Investigating this bank of lysins is aimed at the identification and development of a lead ‘enzybiotic’ with desired PK/PD characteristics against UTI-causing E. coli.

项与 Techinvention Lifecare Pvt Ltd. 相关的新闻（医药）

2024-01-16

·Business Wire

Parasitology and Mycology Rapid Tests and Point of Care (POC) Pipeline Research Report 2023 - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Parasitology and Mycology Rapid Tests and POC Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" report has been added to ResearchAndMarkets.com's offering. Parasitology & Mycology Pipeline Report provides comprehensive information about the Parasitology & Mycology pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. This report provides extensive coverage of Parasitology & Mycology under development, offering comprehensive insights into pipeline products, major players, developmental activities, clinical trial data, and recent developments in the segment/industry. The report reviews the details of major pipeline products, including product descriptions, licensing and collaboration details, and other developmental activities related to Parasitology & Mycology. It also lists all the pipeline projects involving major players engaged in the development of Parasitology & Mycology. Coverage of pipeline products is based on various stages of development, ranging from Early Development to Approved/Issued stages, allowing readers to understand the progress of these products in the pipeline. Key clinical trial data related to ongoing trials specific to pipeline products in the Parasitology & Mycology segment is provided, offering valuable insights into the clinical development of these products. Reasons to Buy Formulate significant competitor information, analysis, and insights to improve R&D strategies Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage Identify and understand important and diverse types of Parasitology & Mycology under development Develop market-entry and market expansion strategies Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline In-depth analysis of the product's current stage of development, territory and estimated launch date Key Topics Covered: 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Parasitology & Mycology Overview 3 Products under Development 3.1 Parasitology & Mycology - Pipeline Products by Stage of Development 3.2 Parasitology & Mycology - Pipeline Products by Territory 3.3 Parasitology & Mycology - Pipeline Products by Regulatory Path 3.4 Parasitology & Mycology - Pipeline Products by Estimated Approval Date 4 Parasitology & Mycology - Pipeline Products under Development by Companies 4.1 Parasitology & Mycology Companies - Pipeline Products by Stage of Development 4.2 Parasitology & Mycology - Pipeline Products by Stage of Development 5 Parasitology & Mycology Companies and Product Overview 6 Parasitology & Mycology- Recent Developments 7 Appendix A selection of companies mentioned in this report includes Abacus Diagnostica Ltd Access Bio Inc Acobiom Adaltis Srl All India Institute of Medical Sciences Antigen Discovery Inc Applied BioCode Inc Aptus Biotech SL Attogene Corp Auburn University Axxin Beckman Coulter Inc BioSynesis Inc Biotechnology Assets SA Biotype Innovation GmbH Cascade Biosystems Inc Cepheid Inc Cerebro Biosystems Ceres Nanosciences Inc Ellume Ltd EUROIMMUN US LLC FK-Biotecnologia SA Foundation for Innovative New Diagnostics Fungea AB G Medical Health and Wellness Genetag Technology, Inc Gennova Biopharmaceuticals Ltd Genome Diagnostics Pvt Ltd George Mason University Great Basin Scientific Inc. HealthTell Inc Immunetics Inc InBios International Inc Institute for Development Research Johns Hopkins University L2 Diagnostics LLC London School of Hygiene & Tropical Medicine Luminex Corp Mahidol Oxford Tropical Medicine Research Unit Masaryk University Massachusetts Institute of Technology McGill University Meridian Bioscience Inc Microbiologics Inc MiraVista Diagnostics LLC MND Diagnostic LTD MycoDART Inc Mylab Discovery Solutions Pvt Ltd Nagasaki University Nanosphere Inc (Inactive) NextGen Invitro Diagnostics Pvt Ltd Novacyt SA Ohio State University OpGen Inc OPKO Health Inc Oregon Health & Science University Ortho Clinical Diagnostics Holdings Plc Pai Life Sciences Inc Paramedical Srl Peruvian Cayetano Heredia University Phagolum Ltd. PixCell Medical Technologies Ltd Praxis Pharmaceutical SAU Proplex Technologies Llc Qiagen NV RealSeq Biosciences Inc Roche Diagnostics International Ltd Seegene Inc Serimmune Inc Siemens Healthcare Diagnostics Inc T2 Biosystems Inc Taizhou ZECEN Biotech Co Ltd Techinvention Lifecare Pvt Ltd The Walter and Eliza Hall Institute of Medical Research Transfusion & Transplantation Technologies (Inactive) University of California University of Colorado University of Edinburgh University of Georgia University of Grenoble Alpes University of Oxford University of Tennessee Virginia Commonwealth University Washington University in St Louis Washington University School of Medicine For more information about this report visit https://www.researchandmarkets.com/r/djd3pp About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

100 项与 Techinvention Lifecare Pvt Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Techinvention Lifecare Pvt Ltd. 相关的转化医学

登录后查看更多信息